表紙:臓器移植診断の世界市場・地域別 - 分析と予測:2021年~2031年
市場調査レポート
商品コード
1031060

臓器移植診断の世界市場・地域別 - 分析と予測:2021年~2031年

Organ Transplant Diagnostics Market - A Global and Regional Analysis: Focus on Offering, Transplant, Application, Technology, End User, and Region - Analysis and Forecast, 2021-2031

出版日: | 発行: BIS Research Inc. | ページ情報: 英文 228 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=115.03円
臓器移植診断の世界市場・地域別 - 分析と予測:2021年~2031年
出版日: 2021年10月04日
発行: BIS Research Inc.
ページ情報: 英文 228 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の臓器移植診断市場は、2031年までに96億6,300万米ドルに達すると予測されています。

市場は、2021年~2031年の予測期間中に、CAGRで10.92%の成長が予測されています。市場の促進要因として、臓器移植手術件数の増加、主要企業による戦略的な取り組み、有利な規制環境などが挙げられます。

当レポートでは、世界の臓器移植診断市場について調査分析し、市場概要、市場力学、競合情勢、主要企業などについて、体系的な情報を提供しています。

目次

第1章 市場

  • 製品定義
  • 市場範囲
  • 市場概要

第2章 業界考察

  • 概要
  • 米国の法的要件とフレームワーク
  • 欧州の法的要件とフレームワーク
  • アジア太平洋地域の法的要件とフレームワーク
  • 償還分析

第3章 市場力学

  • 概要
  • 影響分析
  • 市場促進要因
  • 市場抑制要因
  • 市場機会

第4章 競合情勢

  • 概要
  • 相乗活性
  • 製品発売
  • 製品承認
  • M&A
  • その他の事業活動
  • 市場シェア分析
  • 成長シェア分析 (企業)

第5章 提供

  • 概要
  • 製品
    • キット・アッセイ
    • 消耗品
  • サービス

第6章 移植

  • 概要
  • 固形臓器移植
    • 腎臓
    • 肝臓
    • 心臓
    • 膵臓
    • 腎臓 - 膵臓
    • その他の固形臓器
  • 幹細胞移植

第7章 用途

  • 概要
  • 診断
    • ドナー検査
    • レシピエント検査
  • トランスレーショナルリサーチ

第8章 技術

  • 概要
  • 分子技術
    • ポリメラーゼ連鎖反応 (PCR)
    • シーケンシング
  • 血清
  • フローサイトメトリー (FCM)
  • その他

第9章 エンドユーザー

  • 概要
  • 病院・移植センター
  • 学術・研究機関
  • リファレンスラボラトリーズ
  • その他

第10章 地域

  • 概要
  • 北米
    • 米国
    • カナダ
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • スイス
    • その他の欧州
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア
    • シンガポール
    • その他のアジア太平洋地域
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他のラテンアメリカ
  • その他の地域

第11章 企業プロファイル

  • Thermo Fisher Scientific Inc.
  • QIAGEN N.V.
  • F. Hoffmann-La Roche Ltd.
  • Bio-Rad Laboratories, Inc.
  • Laboratory Corporation of America Holdings
  • bioMerieux S.A.
  • CareDx, Inc.
  • ARUP Laboratories
  • Abbott Laboratories
  • Quest Diagnostics Incorporated
  • Eurofins Scientific
  • Illumina, Inc.
  • OPKO Health
  • Novacyt Group
  • Immucor, Inc,
図表

List of Figures

  • Figure 1: Figure: U.S. Solid Organ and Bone Marrow Transplant Procedures (2017-2020)
  • Figure 2: Impact Analysis of Market Drivers and Market Challenges on the Global Organ Transplant Diagnostics Market
  • Figure 3: Global Organ Transplant Diagnostics Market (by Offering), $Million, 2020 and 2031
  • Figure 4: Global Organ Transplant Diagnostics Market (by Transplant), $Million, 2020 and 2031
  • Figure 5: Global Organ Transplant Diagnostics Market (by Application), $Million, 2020 and 2031
  • Figure 6: Global Organ Transplant Diagnostics Market (by Technology), $Million, 2020 and 2031
  • Figure 7: Global Organ Transplant Diagnostics Market (by End Users), $Million, 2020 and 2031
  • Figure 8: Global Organ Transplant Diagnostics Market Snapshot
  • Figure 9: Global Organ Transplant Diagnostics Market: Research Methodology
  • Figure 10: Primary Research Methodology
  • Figure 11: Bottom-Up Approach (Segment-Wise Analysis)
  • Figure 12: Top-Down Approach (Segment-Wise Analysis)
  • Figure 13: Global Organ Transplant Diagnostics Market Segmentation
  • Figure 14: Global Organ Transplant Diagnostics Market, $Million, 2020-2031
  • Figure 15: Global Organ Transplant Diagnostics Market: COVID-19 Impact Analysis
  • Figure 16: U.S. Solid Organ and Hematopoietic Stem Cell Transplant Data (2017-2020)
  • Figure 17: Share of Key Developments and Strategies, January 2018-September 2021
  • Figure 18: Share of Synergistic Activities (by Company), January 2018-September 2021
  • Figure 19: Number of Product Launches (by Company), January 2018-September 2021
  • Figure 20: Share of Product Approvals (by Company), January 2018-September 2021
  • Figure 21: Share of Mergers and Acquisitions (by Company), January 2018-September 2021
  • Figure 22: Share of Other Business Activities (by Company), January 2018- September 2021
  • Figure 23: Market Share Analysis for Global Organ Transplant Diagnostics Market, $Million, 2019 and 2020
  • Figure 24: Growth Share Analysis for Global Organ Transplant Diagnostics Market (by Company), 2020
  • Figure 25: Figure 8.1: Global Organ Transplant Diagnostics Market (by Offering)
  • Figure 26: Global Organ Transplant Diagnostics Market (by Offering), 2020 and 2031
  • Figure 27: Global Organ Transplant Diagnostics Market (by Product), $Million, 2020-2031
  • Figure 28: Global Organ Transplant Diagnostics Market (Kits and Assays), 2020-2031
  • Figure 29: Global Organ Transplant Diagnostics Market (Consumables), $Million, 2020-2031
  • Figure 30: Global Organ Transplant Diagnostics Market (Services), $Million, 2020-2031
  • Figure 31: Global Organ Transplant Diagnostics Market (Transplant)
  • Figure 32: Global Organ Transplant Diagnostics Market (Transplant), 2020 and 2031
  • Figure 33: Global Organ Transplant Diagnostics Market (by Solid Organ Transplants), $Million, 2020-2031
  • Figure 34: Global Organ Transplant Diagnostics Market (by Solid Organ Transplant), 2020 and 2031
  • Figure 35: Global Organ Transplant Diagnostics Market (Kidney, by Solid Organ Transplants), $Million, 2020-2031
  • Figure 36: Global Organ Transplant Diagnostics Market (Liver, by Solid Organ Transplants), $Million, 2020-2031
  • Figure 37: Global Organ Transplant Diagnostics Market (Heart, by Solid Organ Transplants), $Million, 2020-2031
  • Figure 38: Global Organ Transplant Diagnostics Market (Lung, by Solid Organ Transplants), $Million, 2020-2031
  • Figure 39: Global Organ Transplant Diagnostics Market (Pancreas, by Solid Organ Transplants), $Million, 2020-2031
  • Figure 40: Global Organ Transplant Diagnostics Market (Kidney-Pancreas, by Solid Organ Transplants), $Million, 2020-2031
  • Figure 41: Global Organ Transplant Diagnostics Market (Other Solid Organs, by Solid Organs), $Million, 2020-2031
  • Figure 42: Global Organ Transplant Diagnostics Market (Stem Cell Transplant), $Million, 2020-2031
  • Figure 43: Global Organ Transplant Diagnostics Market (by Application)
  • Figure 44: Global Organ Transplant Diagnostics Market (by Application), $Million, 2020-2031
  • Figure 45: Global Organ Transplant Diagnostics Market (Diagnostics), $Million, 2020-2031
  • Figure 46: Global Organ Transplant Diagnostics Market (by Diagnostics), 2020 and 2031
  • Figure 47: Global Organ Transplant Diagnostics Market (Donor Testing), $Million, 2020-2031
  • Figure 48: Global Organ Transplant Diagnostics Market (by Donor Testing), 2020 and 2031
  • Figure 49: Global Organ Transplant Diagnostics Market (Infectious Disease, by Donor Testing), $Million, 2020-2031
  • Figure 50: Global Organ Transplant Diagnostics Market (Infectious Disease, by Donor Testing), 2020 and 2031
  • Figure 51: Global Organ Transplant Diagnostics Market (Viral, by Donor Testing), $Million, 2020-2031
  • Figure 52: Global Organ Transplant Diagnostics Market (Bacterial, by Donor Testing), $Million, 2020-2031
  • Figure 53: Global Organ Transplant Diagnostics Market (Fungal, by Donor Testing), $Million, 2020-2031
  • Figure 54: Global Organ Transplant Diagnostics Market (Parasitic, by Donor Testing), $Million, 2020-2031
  • Figure 55: Global Organ Transplant Diagnostics Market (HLA Typing, by Donor Testing), $Million, 2020-2031
  • Figure 56: Global Organ Transplant Diagnostics Market (ABO Grouping, by Donor Testing), $Million, 2020-2031
  • Figure 57: Global Organ Transplant Diagnostics Market (Recipient Testing), $Million, 2020-2031
  • Figure 58: Global Organ Transplant Diagnostics Market (by Recipient Testing), 2020 and 2031
  • Figure 59: Global Organ Transplant Diagnostics Market (Infectious Disease, by Recipient Testing), $Million, 2020-2031
  • Figure 60: Global Organ Transplant Diagnostics Market (Infectious Disease, by Recipient Testing), 2020 and 2031
  • Figure 61: Global Organ Transplant Diagnostics Market (Viral, by Recipient Testing), $Million, 2020-2031
  • Figure 62: Global Organ Transplant Diagnostics Market (Bacterial, by Recipient Testing), $Million, 2020-2031
  • Figure 63: Global Organ Transplant Diagnostics Market (Fungal, by Recipient Testing), $Million, 2020-2031
  • Figure 64: Global Organ Transplant Diagnostics Market (Parasitic, by Recipient Testing), $Million, 2020-2031
  • Figure 65: Global Organ Transplant Diagnostics Market (HLA Typing, by Recipient Testing), $Million, 2020-2031
  • Figure 66: Global Organ Transplant Diagnostics Market (ABO Grouping, by Recipient Testing), $Million, 2020-2031
  • Figure 67: Global Organ Transplant Diagnostics Market (Chimerism Testing, by Recipient Testing), $Million, 2020-2031
  • Figure 68: Global Organ Transplant Diagnostics Market (GvHD, by Recipient Testing), $Million, 2020-2031
  • Figure 69: Global Organ Transplant Diagnostics Market (Translational Research), $Million, 2020 - 2031
  • Figure 70: Global Organ Transplant Diagnostics Market (by Technology)
  • Figure 71: Global Organ Transplant Diagnostics Market (by Technology), 2020 and 2021
  • Figure 72: Global Organ Transplant Diagnostics Market (Molecular Technologies), $Million, 2020-2021
  • Figure 73: Global Organ Transplant Diagnostics Market (by Molecular Technologies), 2020 and 2031
  • Figure 74: Global Organ Transplant Diagnostics Market (PCR), $Million, 2021-2031
  • Figure 75: Global Organ Transplant Diagnostics Market (by PCR), 2020 and 2031
  • Figure 76: Global Organ Transplant Diagnostics Market (RT-PCR, by PCR), $Million, 2020 and 2031
  • Figure 77: Global Organ Transplant Diagnostics Market (dPCR, by PCR), $Million, 2020 and 2031
  • Figure 78: Global Organ Transplant Diagnostics Market (Sequencing), $Million, 2020-2031
  • Figure 79: Global Organ Transplant Diagnostics Market (by Sequencing), 2020 and 2031
  • Figure 80: Global Organ Transplant Diagnostics Market (NGS, by Sequencing), $Million, 2020-2031
  • Figure 81: Global Organ Transplant Diagnostics Market (Sanger Sequencing, by Sequencing), $Million, 2020-2031
  • Figure 82: Global Organ Transplant Diagnostics Market (Other Molecular Technologies), $Million, 2020-2031
  • Figure 83: Global Organ Transplant Diagnostics Market (Serology), $Million, 2020-2031
  • Figure 84: Global Organ Transplant Diagnostics Market (Flow Cytometry), $Million, 2020-2031
  • Figure 85: Global Organ Transplant Diagnostics Market (Other Technologies), $Million, 2020-2031
  • Figure 86: Global Organ Transplant Diagnostics Market (by End User)
  • Figure 87: Global Organ Transplant Diagnostics Market (by End User), $Million, 2020 and 2031
  • Figure 88: Global Organ Transplant Diagnostics Market (Hospitals and Transplant Centres), $Million, 2020-2031
  • Figure 89: Global Organ Transplant Diagnostics Market (Academic and Research Institutions), $Million, 2020-2031
  • Figure 90: Global Organ Transplant Diagnostics Market (Reference Laboratories), $Million, 2020-2031
  • Figure 91: Global Organ Transplant Diagnostics Market (Other End Users), $Million, 2020-2031
  • Figure 92: Global Organ Transplant Diagnostics Market (by Region): Market Snapshot
  • Figure 93: Global Organ Transplant Diagnostics Market (by Region), $Million, 2020-2031
  • Figure 94: Global Organ Transplant Diagnostics Market (by Region), 2020 and 2031
  • Figure 95: North America Organ Transplant Diagnostics Market, $Million, 2020-2031
  • Figure 96: North America: Market Dynamics
  • Figure 97: North America Organ Transplant Diagnostics Market (by Country), $Million, 2020-2031
  • Figure 98: U.S. Organ Transplant Diagnostics Market, $Million, 2020-2031
  • Figure 99: Canada Organ Transplant Diagnostics Market, $Million, 2020-2031
  • Figure 100: Europe Organ Transplant Diagnostics Market, $Million, 2020-2031
  • Figure 101: Europe: Market Dynamics
  • Figure 102: Europe Organ Transplant Diagnostics Market (by Country), $Million, 2020-2031
  • Figure 103: Germany Organ Transplant Diagnostics Market, $Million, 2020-2031
  • Figure 104: France Organ Transplant Diagnostics Market, $Million, 2020-2031
  • Figure 105: U.K. Organ Transplant Diagnostics Market, $Million, 2020-2031
  • Figure 106: Italy Organ Transplant Diagnostics Market, $Million, 2020-2031
  • Figure 107: Spain Organ Transplant Diagnostics Market, $Million, 2020-2031
  • Figure 108: Switzerland Organ Transplant Diagnostics Market, $Million, 2020-2031
  • Figure 109: Rest-of-Europe Organ Transplant Diagnostics Market, $Million, 2020-2031
  • Figure 110: Asia-Pacific Organ Transplant Diagnostics Market, $Million, 2020-2031
  • Figure 111: APAC: Market Dynamics
  • Figure 112: APAC Organ Transplant Diagnostics Market (by Country), $Million, 2020-2031
  • Figure 113: China Organ Transplant Diagnostics Market, $Million, 2020-2031
  • Figure 114: India Organ Transplant Diagnostics Market, $Million, 2020-2031
  • Figure 115: Japan Organ Transplant Diagnostics Market, $Million, 2020-2031
  • Figure 116: South Korea Organ Transplant Diagnostics Market, $Million, 2020-2031
  • Figure 117: Australia Organ Transplant Diagnostics Market, $Million, 2020-2031
  • Figure 118: Singapore Organ Transplant Diagnostics Market, $Million, 2020-2031
  • Figure 119: RoAPAC Organ Transplant Diagnostics Market, $Million, 2020-2031
  • Figure 120: Latin America Organ Transplant Diagnostics Market, $Million, 2020-2031
  • Figure 121: Latin America: Market Dynamics
  • Figure 122: Global Organ Transplant Diagnostics Market (by Country), $Million, 2020-2031
  • Figure 123: Brazil Organ Transplant Diagnostics Market, $Million, 2020-2031
  • Figure 124: Mexico Organ Transplant Diagnostics Market, $Million, 2020-2031
  • Figure 125: RoLA Organ Transplant Diagnostics Market, $Million, 2020-2031
  • Figure 126: RoW Organ Transplant Diagnostics Market, $Million, 2020-2031
  • Figure 127: Total Number of Companies Profiled
  • Figure 128: Thermo Fisher Scientific Inc.: Product Portfolio
  • Figure 129: Thermo Fisher Scientific, Inc.: Overall Financials, 2018-2020
  • Figure 130: Thermo Fisher Scientific Inc.: Revenue (by Segment): 2018-2020
  • Figure 131: : Thermo Fisher Scientific Inc.: Revenue (by region), 2018-2020
  • Figure 132: Thermo Fisher Scientific Inc.: R&D Expenditure, 2018-2020
  • Figure 133: : Thermo Fisher Scientific Inc: SWOT Analysis
  • Figure 134: QIAGEN N.V.: Product Portfolio
  • Figure 135: QIAGEN N.V.: Overall Financials, 2018-2020
  • Figure 136: QIAGEN N.V.: Revenue (by Segment), 2018-2020
  • Figure 137: QIAGEN N.V.: Revenue (by Region), 2018-2020
  • Figure 138: QIAGEN N.V.: R&D Expenditure, 2018-2020
  • Figure 139: QIAGEN N.V.: SWOT Analysis
  • Figure 140: F. Hoffmann-La Roche Ltd: Product Portfolio
  • Figure 141: F. Hoffmann-La Roche Ltd: Overall Financials, 2018-2020
  • Figure 142: F. Hoffmann-La Roche Ltd: Revenue (by Segment), 2018-2020
  • Figure 143: F. Hoffmann-La Roche Ltd.: Revenue (by Region), 2018-2020
  • Figure 144: F. Hoffmann-La Roche Ltd.: R&D Expenditure, 2018-2020
  • Figure 145: F. Hoffmann-La Roche Ltd: SWOT Analysis
  • Figure 146: Bio-Rad Laboratories, Inc.: Product Portfolio
  • Figure 147: : Bio-Rad Laboratories, Inc.: Overall Financials, 2018-2020
  • Figure 148: Bio-Rad Laboratories, Inc.: Revenue (by Segment), 2018-2020
  • Figure 149: Bio-Rad Laboratories, Inc.: Revenue (by Region), 2018-2020
  • Figure 150: Bio-Rad Laboratories, Inc.: R&D Expenditure, 2018-2020
  • Figure 151: Bio-Rad Laboratories, Inc.: SWOT Analysis
  • Figure 152: Laboratory Corporation of America Holdings: Service Portfolio
  • Figure 153: Laboratory Corporation of America Holdings: Overall Financials, 2018-2020
  • Figure 154: Laboratory Corporation of America Holdings: Revenue (by Segment), 2018-2020
  • Figure 155: Laboratory Corporation of America Holdings: SWOT Analysis
  • Figure 156: bioMerieux S.A: Product Portfolio
  • Figure 157: bioMerieux S.A.: Overall Financials, 2018-2020
  • Figure 158: bioMerieux S.A.: Revenue (by Segment), 2018-2020
  • Figure 159: bioMerieux S.A.: Revenue (by Region), 2018-2020
  • Figure 160: bioMerieux S.A.: R&D Expenditure, 2018-2020
  • Figure 161: bioMerieux S.A.: SWOT Analysis
  • Figure 162: CareDx Inc.: Product Portfolio
  • Figure 163: CareDx, Inc.: Overall Financials, 2018-2020
  • Figure 164: CareDx, Inc.: Revenue (by Segment), 2018-2020
  • Figure 165: CareDx, Inc.: Revenue (by Region), 2018-2020
  • Figure 166: CareDx, Inc.: R&D Expenditure, 2018-2020
  • Figure 167: CareDx, Inc., SWOT Analysis
  • Figure 168: ARUP Laboratories: Product Portfolio
  • Figure 169: ARUP Laboratories: SWOT Analysis
  • Figure 170: Abbott Laboratories: Product Portfolio
  • Figure 171: Abbott laboratories: Overall Financials, 2018-2020
  • Figure 172: Abbott Laboratories.: Revenue (by Segment), 2018-2020
  • Figure 173: Abbott Laboratories: Revenue (by Region), 2018-2020
  • Figure 174: Abbott Laboratories: R&D Expenditure, 2018-2020
  • Figure 175: Abbott Laboratories: SWOT Analysis
  • Figure 176: Quest Diagnostics Incorporated: Product Portfolio
  • Figure 177: Quest Diagnostics Incorporated: Overall Financials, 2018-2020
  • Figure 178: Quest Diagnostics Incorporated: Revenue (by Segment), 2018-2020
  • Figure 179: Quest Diagnostics Incorporated: SWOT Analysis
  • Figure 180: Eurofins Scientific: Service Portfolio
  • Figure 181: Eurofins Scientific: Overall Financials, 2018-2020
  • Figure 182: Eurofins Scientific: Revenue (by Region), 2018-2020
  • Figure 183: Eurofins Scientific: SWOT Analysis
  • Figure 184: Illumina Inc, Product Portfolio
  • Figure 185: Illumina, Inc, Overall Financials, 2018-2020
  • Figure 186: Illumina, Inc. Revenue (by Segment), 2018-2020
  • Figure 187: Illumina, Inc.: Revenue (by Region), 2018-2020
  • Figure 188: Illumina, Inc: R&D Expenditure, 2018-2020
  • Figure 189: Illumina, Inc: SWOT Analysis
  • Figure 190: OPKO Health: Product Portfolio
  • Figure 191: OPKO Health: Overall Financials, 2018-2020
  • Figure 192: OPKO Health: Revenue (by Region), 2018-2020
  • Figure 193: OPKO Health: R&D Expenditure, 2018-2020
  • Figure 194: OPKO Health: SWOT Analysis
  • Figure 195: Novacyt Group: Product Portfolio
  • Figure 196: Novacyt Group: Overall Financials, 2018-2020
  • Figure 197: Novacyt Group.: Revenue (by Segment): 2018-2020
  • Figure 198: Novacyt Group: R&D Expenditure, 2018-2020
  • Figure 199: Novacyt Group: SWOT Analysis
  • Figure 200: Immucor, Inc: Product Portfolio
  • Figure 201: Immucor, Inc.: SWOT Analysis

List of Tables

  • Table 1: Key Coverage Providers for Organ Transplant Diagnostics Tests
  • Table 2: Likert Scale
  • Table 3: Impact Analysis of Market Drivers
  • Table 4: Impact Analysis of Market Restraints
  • Table 5: Companies Providing Kits and Assays:
  • Table 6: Companies Offering Consumables:
  • Table 7: Table: Companies Offering Consumables:
  • Table 8: RT-PCR-Based Organ Transplant Diagnostic Products
  • Table 9: dPCR-Based Organ Transplant Diagnostic Products
  • Table 10: NGS-Based Organ Transplant Diagnostic Products
  • Table 11: Sanger Sequencing-Based Organ Transplant Diagnostic Products
  • Table 12: Other Technologies-Based Organ Transplant Diagnostic Products
  • Table 13: Serology-Based Organ Transplant Diagnostic Products
  • Table 14: FCM-Based Organ Transplant Diagnostic Products
目次
Product Code: BHP1131SA

“Global Organ Transplant Diagnostics Market to Reach $9,663.0 Million by 2031.”

Market Report Coverage - Organ Transplant Diagnostics

Market Segmentation

  • Offering - Products (Kits and Assays and Consumables) and Services
  • Transplant - Solid Organ Transplant and Stem Cell Transplant
  • Application - Diagnostics (Donor Testing and Recipient Testing) and Translational Research
  • Technology - Molecular Technologies, Serology, Flow Cytometry, and Other Technologies
  • End User - Hospitals and Transplant Centers, Academic and Research Institutions, Reference Laboratories, and Other End Users

Regional Segmentation

  • North America - U.S., and Canada
  • Europe - Germany, France, U.K., Italy, Spain, Switzerland, and Rest-of-Europe
  • Asia-Pacific - China, India, Japan, South Korea, Australia, Singapore, and Rest-of-Asia-Pacific
  • Latin America - Brazil, Mexico, and Rest-of-Latin America
  • Rest-of-the-World

Market Growth Drivers

  • Rising Number of Organ Transplant Procedure
  • Strategic Initiatives by Key Market Players
  • Favorable Regulatory Scenario

Market Challenges

  • High Cost of Organ Transplant Procedure and Diagnostics
  • Lack of Knowledge Dissemination and Reluctance Toward Organ Transplants

Market Opportunities

  • Technological Advancement in Transplant Diagnostics
  • Increasing Awareness Regarding Transplants in High potential Market

Key Companies Profiled

Thermo Fisher Scientific Inc., QIAGEN N.V., F. Hoffmann-La Roche Ltd., Bio-Rad Laboratories, Inc., Laboratory Corporation of America Holdings, bioMerieux S.A., CareDx, Inc., ARUP Laboratories, Abbott Laboratories, Quest Diagnostics Incorporated, Eurofins Scientific, Illumina, Inc., OPKO Health, Novacyt Group, Immucor, Inc.

Key Questions Answered in this Report:

  • How is organ transplant diagnostics revolutionizing the field of transplant care?
  • What are the major market drivers, challenges, and opportunities in the global organ transplant diagnostics market?
  • What are the underlying structures resulting in the emerging trends within the global organ transplant diagnostics market?
  • How did the COVID-19 pandemic impact the global organ transplant diagnostics ecosystem?
  • What are the key development strategies that are being implemented by the major players in order to sustain themselves in the competitive market?
  • What are the key regulatory implications in developed and developing regions pertaining to the use of organ transplant diagnostics?
  • What are the potential entry barriers, which are expected to be faced by the companies willing to enter a particular region?
  • How is each segment of the market expected to grow during the forecast period 2021-2031, and what is the anticipated revenue to be generated by each of the segments? Following are the segments:
    • Offering (products and services)
    • Transplant (solid organ transplant and stem cell transplant)
    • Application (diagnostics and translation research)
    • Technology (molecular technologies, serology, flow cytometry and other technologies)
    • End User (hospitals and transplant centers, academic and research institutions, and reference laboratories)
    • Region (North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World)
  • What are the growth opportunities for the organ transplant diagnostics companies in the region of their operation?
  • Who are the leading players with significant offerings in the global organ transplant diagnostics market?
  • Which companies are anticipated to be highly disruptive in the future, and why?

Market Overview

Our healthcare experts have found the organ transplant diagnostics industry to be one of the most rapidly evolving and dynamic markets, and the global market for organ transplant diagnostics is predicted to grow at a CAGR of 10.92% over the forecast period of 2021-2031. The market is driven by certain factors, which include rising number of organ transplant procedures, strategic initiatives by key market players, and favorable regulatory scenarios.

Currently, the organ transplant diagnostics industry is witnessing an upsurge due to the rising number of organ transplant procedures, strategic initiatives by key market players, and favorable regulatory scenarios are some of the critical factors which are expected to bolster the market growth.

Furthermore, biotechnology companies are focusing on the development of robust organ transplant diagnostics solutions for applications, including diagnostics and translational research, further supporting transplant physicians and researchers to unravel insights pertaining to the intricacies present in the field of transplant care. The development of organ transplant diagnostic products and services enabled transplant physicians to establish effective strategies for organ donor screening and recipient surveillance, further offering value-based care.

Within the research report, the market is segmented on the basis of offering, transplant, application, technology, end users, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.

Competitive Landscape

The exponential rise in the number of organ transplant procedures worldwide has created a buzz among the biotechnology companies to further invest in the development of innovative organ transplant diagnostic tools, further aiding transplant physicians to offer value-based clinical outcomes to transplant patients. Due to the expansive product portfolio and massive geographical presence, Thermo Fisher Scientific Inc. has been the leading player in the organ transplant diagnostics ecosystem.

On the basis of region, North America holds the largest share of the organ transplant diagnostics market due to the presence of well-established guidelines regarding transplant diagnostics, presence of legacy companies undertaking key business strategies, rising number of organ transplants, and increasing adoption of products based on advanced molecular technologies by the transplant physicians, among others. Further, increasing focus on research pertaining to the discovery of novel transplant-associated biomarkers is also expected to support the growth of the North America organ transplant diagnostics market. Apart from this, the Asia-Pacific region is anticipated to grow at the fastest CAGR during the forecast period, 2021-2031.

Table of Contents

1 Markets

  • 1.1 Product Definition
    • 1.1.1 Inclusion and Exclusion
  • 1.2 Market Scope
    • 1.2.1 Scope of the Study
    • 1.2.2 Key Questions Answered in the Report
  • 1.3 Market Overview
    • 1.3.1 Market Definition
    • 1.3.2 Emerging Applications of Organ Transplant Diagnostics
    • 1.3.3 Market Footprint and Growth Potential, $Million, 2020-2031
    • 1.3.4 COVID-19 Impact on the Global Organ Transplant Diagnostics Market

2 Industry Insights

  • 2.1 Overview
  • 2.2 Legal Requirements and Framework in the U.S.
    • 2.2.1 FDA Regulation
    • 2.2.2 CMS Regulation
  • 2.3 Legal Requirements and Frameworks in Europe
  • 2.4 Legal Requirements and Frameworks in Asia-Pacific
    • 2.4.1 China
    • 2.4.2 Japan
  • 2.5 Reimbursement Analysis

3 Market Dynamics

  • 3.1 Overview
  • 3.2 Impact Analysis
  • 3.3 Market Drivers
    • 3.3.1 Rising Number of Organ Transplant Procedure
    • 3.3.2 Strategic Initiatives by Key Market Players
    • 3.3.3 Favorable Regulatory Scenario
  • 3.4 Market Restraints
    • 3.4.1 High Cost of Organ Transplant Procedure and Diagnostics
    • 3.4.2 Lack of Knowledge Dissemination and Reluctance Toward Organ Transplants
  • 3.5 Market Opportunities
    • 3.5.1 Technological Advancement in Transplant Diagnostics
      • 3.5.1.1 Emergence of Nucleic Acid Amplification Testing (NAAT)
      • 3.5.1.2 Growing Focus on Molecular HLA Typing
    • 3.5.2 Increasing Awareness Regarding Transplants in High potential Market

4 Competitive Landscape

  • 4.1 Overview
  • 4.2 Synergistic Activities
  • 4.3 Product Launches
  • 4.4 Product Approvals
  • 4.5 Mergers and Acquisitions
  • 4.6 Other Business Activities
  • 4.7 Market Share Analysis, 2019-2020
  • 4.8 Growth Share Analysis (Company)

5 Offering, $Million, 2020-2031

  • 5.1 Overview
  • 5.2 Products
    • 5.2.1 Kits and Assays
    • 5.2.2 Consumables
  • 5.3 Services

6 Transplant, $Million, 2020-2031

  • 6.1 Overview
  • 6.2 Solid Organ Transplant
    • 6.2.1 Kidney
    • 6.2.2 Liver
    • 6.2.3 Heart
    • 6.2.4 Lung
    • 6.2.5 Pancreas
    • 6.2.6 Kidney-Pancreas
    • 6.2.7 Other Solid Organs
  • 6.3 Stem Cell Transplant

7 Application, $Million, 2020-2031

  • 7.1 Overview
  • 7.2 Diagnostics
    • 7.2.1 Donor Testing
      • 7.2.1.1 Infectious Disease
        • 7.2.1.1.1 Viral
        • 7.2.1.1.2 Bacterial
        • 7.2.1.1.3 Fungal
        • 7.2.1.1.4 Parasitic
      • 7.2.1.2 Human Leukocyte Antigen (HLA) Typing
      • 7.2.1.3 ABO Grouping
    • 7.2.2 Recipient Testing
      • 7.2.2.1 Infectious Disease
        • 7.2.2.1.1 Viral
        • 7.2.2.1.2 Bacterial
        • 7.2.2.1.3 Fungal
        • 7.2.2.1.4 Parasitic
      • 7.2.2.2 Human Leukocyte Antigen (HLA) Typing
      • 7.2.2.3 ABO Grouping
      • 7.2.2.4 Chimerism Testing
      • 7.2.2.5 Graft versus Host Disease (GvHD)
  • 7.3 Translational Research

8 Technology, $Million, 2020-2031

  • 8.1 Overview
  • 8.2 Molecular Technologies
    • 8.2.1 Polymerase Chain Reaction (PCR)
      • 8.2.1.1 Real-Time PCR (RT-PCR)
      • 8.2.1.2 Digital PCR (dPCR)
    • 8.2.2 Sequencing
      • 8.2.2.1 Next-Generation Sequencing (NGS)
      • 8.2.2.2 Sanger Sequencing
      • 8.2.2.3 Other Molecular Technologies
  • 8.3 Serology
  • 8.4 Flow Cytometry (FCM)
  • 8.5 Other Technologies

9 End-User, $Million, 2020-2031

  • 9.1 Overview
  • 9.2 Hospitals and Transplant Centers
  • 9.3 Academic and Research Institutions
  • 9.4 Reference Laboratories
  • 9.5 Other End Users

10 Regions, $Million, 2020-2031

  • 10.1 Overview
  • 10.2 North America
    • 10.2.1 U.S.
    • 10.2.2 Canada
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 France
    • 10.3.3 U.K.
    • 10.3.4 Italy
    • 10.3.5 Spain
    • 10.3.6 Switzerland
    • 10.3.7 Rest-of-Europe
  • 10.4 Asia-Pacific
    • 10.4.1 China
    • 10.4.2 India
    • 10.4.3 Japan
    • 10.4.4 South Korea
    • 10.4.5 Australia
    • 10.4.6 Singapore
    • 10.4.7 Rest-of-Asia-Pacific (RoAPAC)
  • 10.5 Latin America
    • 10.5.1 Brazil
    • 10.5.2 Mexico
    • 10.5.3 Rest-of-Latin America (RoLA)
  • 10.6 Rest-of-the-World

11 Company Profiles

  • 11.1 Overview
  • 11.2 Thermo Fisher Scientific Inc.
    • 11.2.1 Company Overview
    • 11.2.2 Role of Thermo Fisher Scientific Inc. in the Global Organ Transplant Diagnostics Market
    • 11.2.3 Financials
    • 11.2.3 Key Insights About Financial Health of the Company
    • 11.2.4 SWOT Analysis
  • 11.3 QIAGEN N.V.
    • 11.3.2 Company Overview
    • 11.3.3 Role of QIAGEN N.V. in the Global Organ Transplant Diagnostics Market
    • 11.3.4 Financials
    • 11.3.5 Key Insights About Financial Health of the Company
    • 11.3.6 SWOT Analysis
  • 11.4 F. Hoffmann-La Roche Ltd.
    • 11.4.2 Company Overview
    • 11.4.3 Role of F. Hoffmann-La Roche Ltd in the Global Organ Transplant Diagnostics Market
    • 11.4.4 Financials
    • 11.4.5 Key Insights About Financial Health of the Company
    • 11.4.6 SWOT Analysis
  • 11.5 Bio-Rad Laboratories, Inc.
    • 11.5.2 Company Overview
    • 11.5.3 Role of Bio-Rad Laboratories, Inc. in the Global Organ Transplant Diagnostics Market
    • 11.5.4 Financials
    • 11.5.5 Key Insights About Financial Health of the Company
    • 11.5.6 SWOT Analysis
  • 11.6 Laboratory Corporation of America Holdings
    • 11.6.2 Company Overview
    • 11.6.3 Role of Laboratory Corporation of America Holdings in the Global Organ Transplant Diagnostics Market
    • 11.6.4 Financials
    • 11.6.5 SWOT Analysis
  • 11.7 bioMerieux S.A.
    • 11.7.2 Company Overview
    • 11.7.3 Role of bioMerieux S.A. in the Global Organ Transplant Diagnostics Market
    • 11.7.4 Financials
    • 11.7.5 Key Insights About Financial Health of the Company
    • 11.7.6 SWOT Analysis
  • 11.8 CareDx, Inc.
    • 11.8.2 Company Overview
    • 11.8.3 Role of CareDx, Inc. in the Global Organ Transplant Diagnostics Market
    • 11.8.4 Financials
    • 11.8.5 Key Insights About Financial Health of the Company
    • 11.8.6 SWOT Analysis
  • 11.9 ARUP Laboratories
    • 11.9.2 Company Overview
    • 11.9.3 Role of ARUP Laboratories in the Global Organ Transplant Diagnostics Market
    • 11.9.4 SWOT Analysis
  • 11.1 Abbott Laboratories
    • 11.10.2 Company Overview
    • 11.10.3 Role of Abbott Laboratories in the Global Organ Transplant Market
    • 11.10.4 Financials
    • 11.10.5 Key Insights About Financial Health of the Company
    • 11.10.6 SWOT Analysis
  • 11.11 Quest Diagnostics Incorporated
    • 11.11.2 Company Overview
    • 11.11.3 Role of Quest Diagnostics Incorporated in the Global Organ Transplant Diagnostics Market
    • 11.11.4 Financials
    • 11.11.5 SWOT Analysis
  • 11.12 Eurofins Scientific
    • 11.12.2 Company Overview
    • 11.12.3 Role of Eurofins Scientific in the Global Organ Transplant Diagnostics Market
    • 11.12.4 Financials
    • 11.12.5 SWOT Analysis
  • 11.13 Illumina, Inc.
    • 11.13.2 Company Overview
    • 11.13.3 Role of Illumina, Inc. in the Global Organ Transplant Diagnostics Market
    • 11.13.4 Financials
    • 11.13.5 Key Insights About Financial Health of the Company
    • 11.13.6 SWOT Analysis
  • 11.14 OPKO Health
    • 11.14.2 Company Overview
    • 11.14.3 Role of OPKO Health in the Global Organ Transplant Diagnostics Market
    • 11.14.4 Financials
    • 11.14.5 Key Insights About Financial Health of the Company
    • 11.14.6 SWOT Analysis
  • 11.15 Novacyt Group
    • 11.15.2 Company Overview
    • 11.15.3 Role of Novacyt Group in the Global Organ Transplant Diagnostics Market
    • 11.15.4 Financials
    • 11.15.5 Key Insights About Financial Health of the Company
    • 11.15.6 SWOT Analysis
  • 11.16 Immucor, Inc,
    • 11.16.2 Company Overview
    • 11.16.3 Role of Immucor, Inc. in the Global Organ Transplant Diagnostics Market
    • 11.16.4 SWOT Analysis